Bathi sadurunge bunga, pajak, lan amortisasi: tevogen.com (TVGN)

Tevogen Bio Holdings (TVGN) has optimized costs by outsourcing drug production to external CDMO partners. Operating cash flow before interest and taxes confirms a lack of profit, where 0.00 is recorded as the baseline value. The company is developing affordable T-cell cancer therapy via its proprietary platform. However, the absence of revenue and reliance on secondary offerings during early-stage clinical trials create high investment risks.

For investors, evaluating Tevogen Bio Holdings (TVGN) requires an analysis of the company's ability to generate cash flow during a period of intensive R&D for T-cell therapies. The projected EBITDA reflects the actual volume of operating cash inflow before depreciation and interest, determining whether internal resources are sufficient to scale personalized medicine without a critical dependence on costly external financing or the risk of capital freezes.